

Gold Sponsors



Silver Sponsors



Media Partners



Exhibition

AbD Serotec
Blutspendedienst des BRK GmbH
CellTool GmbH
CryoShop.de
Definiens AG
IMG LABORATORIES GmbH
Iris Biotech GmbH
LI-COR Biosciences GmbH
Münchener Studienzentrum
Nanostring Technologies Inc.
Novumed GmbH
PSI CRO AG
PolyQuant GmbH
Scienion AG

Registration Fee

Industry rate
290 Euro + VAT with dinner/networking event
270 Euro + VAT without dinner/networking event

Academic rate
190 Euro + VAT with dinner/networking event
170 Euro + VAT without dinner/networking event

Conference Homepage

www.m4.de/mbc

Venue

Hilton Munich Park Hotel
Am Tucherpark 7
D-80538 München

www.hilton.de/muenchenpark

Contact

Bio^M Biotech Cluster Development GmbH
Am Klopferspitz 19a
D-82152 Martinsried

Phone +49 (0) 89 89 96 79 0
Fax +49 (0) 89 89 96 79 79
Email info@bio-m.org
Web www.bio-m.org

The m⁴ leading-edge cluster is sponsored by



2nd Munich Biomarker Conference

Programme

November 22nd - 23rd, 2012

Hilton Munich Park Hotel



Welcome to the 2nd Munich Biomarker Conference



With the increasing requirements of the regulatory authorities regarding safety and efficacy of new therapeutics, there is a growing need to stratify patient populations with reliable biomarkers. However, the co-development of drugs and biomarkers faces several challenges and requires close interaction of different players along the value added chain.

Munich is a perfect place to discuss the future of precision medicine, as the location is characterized by a close network of excellent life science institutes and hospitals as well as cutting-edge biotech companies, especially in the field of drug development. Furthermore, Munich has sharpened its profile with the BMBF funding programme *m⁴ – Personalized Medicine and Targeted Therapies*. Innovative therapies and technologies are being developed and solutions are created for current issues such as biobanking, clinical trial design, data management and technology transfer.

The 2nd Munich Biomarker Conference will showcase recent progress in biomarker research – from biomarker identification to examples for the clinical implementation of personalized medicine. With a wide variety of methods and technologies, the conference will provide exciting insights, as well as an excellent basis for new co-operations. Furthermore, experts will comment on the necessary framework conditions and regulatory requirements of drug development with companion diagnostics.

I wish all participants an interesting meeting and fruitful discussions with colleagues and experts in the field.

Horst Domdey
Bio^M Biotech Cluster Development GmbH
Spokesman of the Munich Biotech Cluster m⁴

Find out more about m⁴ at: www.m4.de

www.m4.de



Thursday, November 22nd

09:00 Welcome
Horst Domdey, Bio^M Biotech Cluster Development GmbH

09:20 Keynote
Oncologically relevant biomarkers as a basis for personalized therapy – status quo and perspectives
Manfred Dietel, Charité Berlin

Oncology

Chair: Christian Peschel, Klinikum rechts der Isar, Munich

09:50 Biomarkers for metastatic disease recurrence in colorectal cancer
Klaus-Peter Janssen, TU München

10:10 Alternative splicing of BRAF in colorectal cancer and characterization of novel variants
Benjamin Hirschi, LMU München

10:30 Coffee Break

11:00 Keynote Oncology
Ralf Schumacher, Roche Penzberg

11:30 Micro-RNA biomarkers - unraveling clinical implications by *in situ* detection in FFPE
Boye S. Nielsen, Bioneer A/S, Hørsholm, DK

11:50 Diagnostic development for certain cancers - a combinational approach
Robert Löwe, GeneWake GmbH, Neuried

12:10 DNA methylation markers for disease progression and survival in Barrett's esophagus
Marc Tänzer, Klinikum rechts der Isar, Munich

12:30 Lunch Break

13:30 Poster Session

13:30 Company Workshop
Accelrys Ltd., Cambridge, UK 

Biomarker-driven clinical studies

Chair: Michael Herschel, GlaxoSmithKline, Munich

14:30 Panel discussion
Does stratification increase safety and efficacy of new therapeutics?
Tomasz Burzykowski, IDDI, Louvain-la-Neuve, BE
Thomas Kaiser, IQWiG, Cologne
Peter Schulz-Knappe, Protagen AG, Dortmund
Martin Langanke, Greifswald

16:00 Coffee Break

Health technology assessment

Chair: Ulrich Mansmann, LMU, München

16:30 Panel discussion
Is personalized healthcare economically advantageous?
Eddie Blair, Integrated Medicines Ltd., Cambridge, UK
Hartmut Döhner, Universitätsklinikum Ulm
Uwe Siebert, UMIT, Hall, AT

18:30 Dinner and networking event

Friday, November 23rd

09:00 Opening
Horst Domdey, Bio^M Biotech Cluster Development GmbH

09:10 Keynote
Is personalized medicine an attractive business proposition? - The example of *in vivo* molecular imaging
Hans Maier, BGM Associates, Berlin

Diabetes and metabolic diseases

Chair: Horst Domdey, Bio^M

09:40 Serum metabolites and risk of type 2 diabetes: a targeted metabolomic approach
Anna Flögel, Dt. Institut für Ernährungsforschung, Potsdam

10:00 Towards the identification of disease network biomarkers in metabolomics data
Jan Krumsiek, Helmholtz Zentrum München

10:20 Metabolite profiling identifies early diabetic changes leveraging marker candidates for therapeutic targets
Patricia Ruiz Noppinger, Metanomics Health, Berlin

10:40 Coffee Break

Cardiovascular Diseases

Chair: Stefan Engelhardt, LMU München

11:10 Cardiovascular biomarkers: the rocky road from discovery to clinical application
Kai Wollert, Medizinische Hochschule Hannover

11:30 Biomarker-based personalized medicine in cardiac arrhythmia management: hype or hope?
Stefan Kääh, LMU München

Autoimmune and inflammatory diseases

Chair: Bernhard Hemmer, Klinikum rechts der Isar, Munich

11:50 Biomarker research in multiple sclerosis
Roland Martin, Universitätsspital Zürich, CH

12:10 Implementing microRNA biomarkers for non-invasive diagnosis of diseases
Markus Beier, Comprehensive Biomarker Center, Heidelberg

12:30 Lunch Break

Parallel Satellite Meetings

13:30 Biobanking for personalized medicine – how can a sustainable infrastructure be achieved?

Chair: Karl-Walter Jauch, Klinikum der Universität München
Hartmut Juhl, Individumed, Hamburg
Karine Sargsyan, Biobank Graz, AT
Jürgen W. Goebel, AG Biomaterialbanken, TMF e.V.
Thomas Singer, Roche Basel, CH

13:30 Diagnostics for personalized medicine – does the development of new imaging diagnostics pay off?

Chair: Peter Bartenstein, LMU München
Hans Maier, BGM Associates, Berlin
Christof Krummeich, BfArM, Bonn
Martina Kaufmann, M. K. Strategic Consulting, Müllheim
Ernst Rummeny, Klinikum rechts der Isar, Munich
Olaf Wilhelm, Willex AG, Munich

13:30 EuroBioForum Meeting (by invitation only)
Chair: Wouter Spek, EuroBioForum, The Hague, NL

15:30 End of Conference

